Dizal: ZEGFROVY®Sunvozertinib, developed by Dizal Pharmaceutical, is poised to reshape the global first-line treatment landscape for EGFR exon20ins NSCLC with its pivotal Phase III study.
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Dizal Pharmaceutical presented three latest research advances in non-small cell lung cancer (NSCLC), covering three products: Sunvozertinib (Sunvozertinib®), DZD6008, and Golidocitinib (Gaoreize®). Among these, the international multicenter Phase III study of Sunvozertinib, WU-KONG28, was featured as a Late-Breaking Abstract (LBA) oral presentation.
The full study was simultaneously published in The New England Journal of Medicine (NEJM), a top-tier international medical journal. Sunvozertinib is the world’s first and only oral targeted monotherapy validated by a global, multicenter, randomized controlled Phase III clinical study in the first-line treatment of EGFR exon20ins NSCLC. The study results demonstrated that Sunvozertinib monotherapy showed statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared with platinum-based doublet chemotherapy in the first-line treatment of EGFR exon20ins NSCLC.
Buy ZEGFROVY®（Sunvozertinib） online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
